pacman schreef op 19 januari 2021 15:49:
[...]
The rabbit-based production of rhC1INH is very scalable; up-scaling can be executed rapidly
• To serve future potential large indications in a more economical way, Pharming will restart
its previously-developed and characterized cattle-based production lines of rhC1INH
• Clinical programs could be initiated with RUCONEST and switched to cattle version during
program following conversion studies
• Cattle-derived rhC1INH may have some benefits over the current rabbit version, including
an extended serum half-life as result of an improved (even closer to human) glycosylation
pattern
• New IP to be filed on the cattle-derived rhC1INH
mooi he , even closer to human